Takeda Pharmaceutical Co. Ltd. (TAK)

17.16
0.22 1.27
NYSE : Health Technology
Prev Close 17.38
Open 17.31
Day Low/High 17.14 / 17.31
52 Wk Low/High 15.50 / 21.95
Volume 924.38K
Avg Volume 1.94M
Exchange NYSE
Shares Outstanding 3.13B
Market Cap 54.81B
EPS 0.50
Div & Yield 0.62 (3.68%)

Latest News

Takeda Unveil New Data From The PROPEL Study At ISTH 2019, Reinforcing The Potential Benefit For Personalized Prophylaxis With ADYNOVATE In Severe Hemophilia A

Takeda Unveil New Data From The PROPEL Study At ISTH 2019, Reinforcing The Potential Benefit For Personalized Prophylaxis With ADYNOVATE In Severe Hemophilia A

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda"), R&D-driven, global biopharmaceutical company with a leadership position in rare diseases, has today announced updated results from its phase IIIb/IV clinical trial for ADYNOVATE ®...

Takeda To Demonstrate Global Leadership In Hematology At ISTH 2019

Takeda To Demonstrate Global Leadership In Hematology At ISTH 2019

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK) ("Takeda"), the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and...

Takeda Completes Sale Of Xiidra® To Novartis

Takeda Completes Sale Of Xiidra® To Novartis

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK) ("Takeda") today announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Takeda Pharmaceutical Company Limited - TAK

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Takeda Pharmaceutical Company Limited - TAK

NEW YORK, June 28, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or the "Company") (NYSE: TAK).

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Takeda Pharmaceutical Company Limited And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Takeda Pharmaceutical Company Limited And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Takeda Pharmaceutical Company Limited ("Takeda" or "the Company") (NYSE: TAK ) for violations of §§10(b) and 20(a) of...

Takeda Announces The Publication Of Its Annual Report On Form 20-F For FY2018

Takeda Announces The Publication Of Its Annual Report On Form 20-F For FY2018

Takeda Pharmaceutical Company Limited ("Takeda") ( TOKYO:4502/NYSE:TAK ) hereby announces that it has filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2019 (the "Annual Report") with the U.

Takeda Selects Five New Partnerships For Annual Global Corporate Social Responsibility (CSR) Program, Supporting Disease Prevention To Improve Health In Developing And Emerging Countries

Takeda Selects Five New Partnerships For Annual Global Corporate Social Responsibility (CSR) Program, Supporting Disease Prevention To Improve Health In Developing And Emerging Countries

Takeda Pharmaceutical Company Limited ( TOKYO:4502/NYSE:TAK) ("Takeda") today announced the addition of five partners to its Global CSR Program for 2019, which contributes to the long-term health of people through disease prevention and capacity building...

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Takeda Pharmaceutical Company Limited - TAK

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Takeda Pharmaceutical Company Limited - TAK

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Takeda Pharmaceutical Company Limited (NYSE: TAK) resulting from allegations that Takeda may have issued materially...

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal

The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.

Takeda Provides Update On TOURMALINE-AL1 Phase 3 Trial In AL Amyloidosis

Takeda Provides Update On TOURMALINE-AL1 Phase 3 Trial In AL Amyloidosis

Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE: TAK) today announced that the Phase 3 TOURMALINE-AL1 clinical trial in patients with relapsed or refractory systemic light-chain (AL) amyloidosis did not meet the first of two primary endpoints.

Takeda Presents Results From Lung Portfolio Including Phase 1/2 Study Of TAK-788 In A Rare Form Of NSCLC And New Data On Overall Health-Related Quality Of Life For ALUNBRIG® (brigatinib)

Takeda Presents Results From Lung Portfolio Including Phase 1/2 Study Of TAK-788 In A Rare Form Of NSCLC And New Data On Overall Health-Related Quality Of Life For ALUNBRIG® (brigatinib)

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that new data for TAK-788 will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 3 at 10:12 a.

New Ad-hoc Analysis Of Phase 3 HELP Study™ Evaluates Prevention Of HAE Attacks With TAKHZYRO® (lanadelumab) During Early Treatment Phase

New Ad-hoc Analysis Of Phase 3 HELP Study™ Evaluates Prevention Of HAE Attacks With TAKHZYRO® (lanadelumab) During Early Treatment Phase

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK) ("Takeda") today announced new data from an ad-hoc analysis of the Phase 3 HELP Study™, designed to evaluate the onset of action for TAKHZYRO ® (lanadelumab) during days 0-69 of treatment.

Takeda Makes First Private Sector Pledge For Global Fund Replenishment

Takeda Makes First Private Sector Pledge For Global Fund Replenishment

Takeda Pharmaceutical Company Limited ("Takeda") ( TSE:4502/NYSE:TAK) today became the first private sector company to announce a financial commitment to the Global Fund's Sixth Replenishment.

Takeda To Showcase Growing Pipeline And Diversified Portfolio Of Oncology Products At Upcoming Scientific Congresses

Takeda To Showcase Growing Pipeline And Diversified Portfolio Of Oncology Products At Upcoming Scientific Congresses

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) today announced that the company will present data at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31-June 4 in Chicago and the 24 th Congress of the European...

Takeda To Highlight Compelling New Data And Portfolio Advances For Gastrointestinal (GI) Diseases At DDW 2019

Takeda To Highlight Compelling New Data And Portfolio Advances For Gastrointestinal (GI) Diseases At DDW 2019

− 18 Takeda-sponsored abstracts investigating Entyvio® (vedolizumab) in ulcerative colitis (UC) and Crohn's disease (CD) will be presented

Takeda And London School Of Hygiene & Tropical Medicine Establish "Takeda Chair In Global Child Health"

Takeda And London School Of Hygiene & Tropical Medicine Establish "Takeda Chair In Global Child Health"

Takeda Pharmaceutical Company Limited ( TOKYO:4502/NYSE:TAK) ("Takeda") and the London School of Hygiene & Tropical Medicine (LSHTM) will announce today at the evening reception, hosted by the Embassy of Japan in the United Kingdom, the establishment of...

Takeda And Frazier Healthcare Partners Announce Collaboration To Launch Phathom Pharmaceuticals

Takeda And Frazier Healthcare Partners Announce Collaboration To Launch Phathom Pharmaceuticals

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK) ("Takeda") and Frazier Healthcare Partners ("Frazier") today announced a collaboration to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and...

Takeda Celebrates MPS Awareness Day In Recognition Of The Seven Rare MPS Diseases

Takeda Celebrates MPS Awareness Day In Recognition Of The Seven Rare MPS Diseases

LEXINGTON, Mass., May 15, 2019 /PRNewswire/  -- Be #MPSAware for MPS Awareness Day 2019.

Takeda To Highlight New Research Into The Long-term Complications Of Chronic Hypoparathyroidism At The European Congress Of Endocrinology 2019 Annual Meeting

Takeda To Highlight New Research Into The Long-term Complications Of Chronic Hypoparathyroidism At The European Congress Of Endocrinology 2019 Annual Meeting

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK) ("Takeda") today announced that it will feature 7 presentations, including one oral presentation, at the upcoming European Congress of Endocrinology (ECE) Annual Meeting from May 18-21, 2019 in...

FY2018 Reported Results In Detail And FY2019 Forecast

FY2018 Reported Results In Detail And FY2019 Forecast

Takeda Pharmaceutical Company Limited (TOKYO:4502)(NYSE:TAK): This press release features multimedia.

Takeda Simplifies Portfolio And Accelerates Deleveraging Through Two Divestitures

Takeda Simplifies Portfolio And Accelerates Deleveraging Through Two Divestitures

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it has entered into agreements to divest its Xiidra ® (lifitegrast ophthalmic solution) 5% product ("Xiidra ®") to Novartis and its TachoSil ® Fibrin Sealant Patch...

Takeda Expands Oncology Research, Demonstrating Commitment To Patient Community At 15th International Symposium On Myelodysplastic Syndromes

Takeda Expands Oncology Research, Demonstrating Commitment To Patient Community At 15th International Symposium On Myelodysplastic Syndromes

Takeda Pharmaceutical Company Limited [TSE: 4502 / NYSE: TAK] today announced that it will present a total of five company-sponsored poster presentations, as well as an oral pipeline symposium, at the 15 th International Symposium on Myelodysplastic...

Takeda Opens New Global Research Center In San Diego

Takeda Opens New Global Research Center In San Diego

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK) ("Takeda") today announced the opening of a new research facility in San Diego, California.

Takeda Presents New Data At The Endocrine Society's 2019 Annual Meeting About The Patient Burden And Long-Term Impact Of Chronic Hypoparathyroidism

Takeda Presents New Data At The Endocrine Society's 2019 Annual Meeting About The Patient Burden And Long-Term Impact Of Chronic Hypoparathyroidism

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK) ("Takeda") this week shared new data revealing the burden of chronic hypoparathyroidism on patients and caregivers, as well as potential long-term risks of renal and cardiovascular complications...

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

Industry Consortium Launched To Qualify Biomarkers For Schizophrenia Drug Development

The ERP Biomarker Qualification Consortium was launched today by pharmaceutical industry members with the goal of qualifying event-related potential (ERP) biomarkers to aid the development of new investigational therapies for people with schizophrenia in...

Takeda Receives U.S. FDA Approval To Manufacture FLEXBUMIN® At New Plasma Manufacturing Facility Near Covington, Georgia

Takeda Receives U.S. FDA Approval To Manufacture FLEXBUMIN® At New Plasma Manufacturing Facility Near Covington, Georgia

Takeda Pharmaceutical Company Limited ( TOKYO:4502/NYSE:TAK), ("Takeda") today announced that the United States Food and Drug Administration (FDA) has approved the company's second submission for its new plasma manufacturing facility near Covington,...

Vedolizumab (Entyvio®) Achieves Superior Rates Of Clinical Remission Vs. Adalimumab (Humira®) In First Ever Head-to-Head Biologic Clinical Study In Ulcerative Colitis

Vedolizumab (Entyvio®) Achieves Superior Rates Of Clinical Remission Vs. Adalimumab (Humira®) In First Ever Head-to-Head Biologic Clinical Study In Ulcerative Colitis

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK) ("Takeda") today announced results from the Phase 3b head-to-head VARSITY study which demonstrated that the gut-selective biologic vedolizumab (Entyvio ®) was superior to the anti-tumor necrosis...